Chinese General Practice ›› 2021, Vol. 24 ›› Issue (20): 2580-2588.DOI: 10.12114/j.issn.1007-9572.2021.00.559
Special Issue: 肿瘤最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2021-07-15
Online:
2021-07-15
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.00.559
[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.DOI:10.3322/caac.21492. [2]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.005. ZHENG R S,SUN K X,ZHANG S W,et al.Report of cancer epidemiology in China,2015[J].Chinese Journal of Oncology,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.005. [3]GU X Y,ZHENG R S,XIA C F,等.中国预期寿命与癌症发病率和死亡率的相互影响:基于人群的聚类分析[J].癌症,2019,38(1):23-38.https://d.wanfangdata.com.cn/periodical/ez201901003. [4]马春光,叶定伟,李长岭,等.前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J].中华外科杂志,2008,46(12):921-925. MA C G,YE D W,LI C L,et al.Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease[J].Chinese Journal of Surgery,2008,46(12):921-925. [5]ANDRIOLE G L,BOSTWICK D,BRAWLEY O W,et al.The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy:results from the REDUCE study[J].J Urol,2011,185(1):126-131.DOI:10.1016/j.juro.2010.09.011. [6]ABDOLLAH F,NOVARA G,BRIGANTI A,et al.Trans-rectal versus trans-perineal saturation rebiopsy of the prostate:is there a difference in cancer detection rate?[J].Urology,2011,77(4):921-925.DOI:10.1016/j.urology.2010.08.048. [7]CATALONA W J,PARTIN A W,SLAWIN K M,et al.Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease:a prospective multicenter clinical trial[J].JAMA,1998,279(19):1542-1547.DOI:10.1001/jama.279.19.1542. [8]CRAWFORD E D,ROVE K O,TRABULSI E J,et al.Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen:a prospective study of 1,962 cases[J].J Urol,2012,188(5):1726-1731.DOI:10.1016/j.juro.2012.07.023. [9]THOMPSON I M,ANKERST D P,CHI C,et al.Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower[J].JAMA,2005,294(1):66-70.DOI:10.1001/jama.294.1.66. [10]WOLF A M,WENDER R C,ETZIONI R B,et al.American Cancer Society guideline for the early detection of prostate cancer:update 2010[J].CA Cancer J Clin,2010,60(2):70-98.DOI:10.3322/caac.20066. [11]MASUDA T,HAYASHI N,IGUCHI T,et al.Clinical and biological significance of circulating tumor cells in cancer[J].Mol Oncol,2016,10(3):408-417.DOI:10.1016/j.molonc.2016.01.010. [12]SCHWARZENBACH H,ALIX-PANABIèRES C,MüLLER I, et al.Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer[J].Clin Cancer Res,2009,15(3):1032-1038.DOI:10.1158/1078-0432.CCR-08-1910. [13]PéREZ-BARRIOS C,NIETO-ALCOLADO I,TORRENTE M,et al.Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients:impact on biomarker testing[J].Transl Lung Cancer Res,2016,5(6):665-672.DOI:10.21037/tlcr.2016.12.03. [14]LU T,LI J M.Clinical applications of urinary cell-free DNA in cancer:current insights and promising future[J].Am J Cancer Res,2017,7(11):2318-2332. [15]DI MEO A,BARTLETT J,CHENG Y,et al.Liquid biopsy:a step forward towards precision medicine in urologic malignancies[J].Mol Cancer,2017,16(1):80.DOI:10.1186/s12943-017-0644-5. [16]PALMIROTTA R,LOVERO D,CAFFORIO P,et al.Liquid biopsy of cancer:a multimodal diagnostic tool in clinical oncology[J].Ther Adv Med Oncol,2018,10:1758835918794630.DOI:10.1177/1758835918794630. [17]DIAZ L A Jr,BARDELLI A.Liquid biopsies:genotyping circulating tumor DNA[J].J Clin Oncol,2014,32(6):579-586.DOI:10.1200/JCO.2012.45.2011. [18]FLEISCHHACKER M,SCHMIDT B.Circulating nucleic acids(CNAs)and cancer——a survey[J].Biochim Biophys Acta,2007,1775(1):181-232.DOI:10.1016/j.bbcan.2006.10.001. [19]ELSHIMALI Y I,KHADDOUR H,SARKISSYAN M,et al.The clinical utilization of circulating cell free DNA(CCFDNA)in blood of cancer patients[J].Int J Mol Sci,2013,14(9):18925-18958.DOI:10.3390/ijms140918925. [20]WHITING P F,RUTJES A W,WESTWOOD M E,et al.QUADAS-2:a revised tool for the quality assessment of diagnostic accuracy studies[J].Ann Intern Med,2011,155(8):529-536.DOI:10.7326/0003-4819-155-8-201110180-00009. [21]张俊,徐志伟,李克.诊断性试验Meta分析的效应指标评价[J].中国循证医学杂志,2013,13(7):890-895. ZHANG J,XU Z W,LI K.Evaluation on the effect index of diagnostic test[J].Chin J Evid - Based Med,2013,13(7):890-895. [22]LIU B,LIU Y L,PAN X X,et al.DNA methylation markers for Pan-cancer prediction by deep learning[J].Genes(Basel),2019,10(10):E778.DOI:10.3390/genes10100778. [23]NEKRASOV K A,VIKARCHUK M V,RUDENKO E E,et al.6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage[J].Oncol Lett,2019,18(6):6917-6925.DOI:10.3892/ol.2019.11015. [24]HENDRIKS R J,DIJKSTRA S,SMIT F P,et al.Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients[J].Prostate,2018,78(5):336-342.DOI:10.1002/pros.23477. [25]FAWZY A,SWEIFY K M,EL-FAYOUMY H M,et al.Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence[J].J Egypt Natl Canc Inst,2016,28(4):235-242.DOI:10.1016/j.jnci.2016.08.003. [26]REIS I M,RAMACHANDRAN K,SPEER C,et al.Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease[J].Br J Cancer,2015,113(3):460-468.DOI:10.1038/bjc.2015.240. [27]WANG L,LIN Y L,LI B,et al.Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer[J].J Int Med Res,2014,42(5):1085-1092.DOI:10.1177/0300060514540631. [28]WROCLAWSKI M L,SERPA-NETO A,FONSECA F L,et al.Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients[J].Tumour Biol,2013,34(5):2921-2927.DOI:10.1007/s13277-013-0854-4. [29]JIANG F,FENG G,XIAO L,et al.Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen[J].Int Urol Nephrol,2013,45(4):1023-1028.DOI:10.1007/s11255-013-0491-2. [30]OKEGAWA T,NUTAHARA K,HIGASHIHARA E.Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer[J].Int J Urol,2010,17(5):466-475.DOI:10.1111/j.1442-2042.2010.02502.x. [31]SUNAMI E,SHINOZAKI M,HIGANO C S,et al.Multimarker circulating DNA assay for assessing blood of prostate cancer patients[J].Clin Chem,2009,55(3):559-567.DOI:10.1373/clinchem.2008.108498. [32]BRYZGUNOVA O E,MOROZKIN E S,YARMOSCHUK S V,et al.Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients[J].Ann N Y Acad Sci,2008,1137:222-225.DOI:10.1196/annals.1448.039. [33] ELLINGER J,HAAN K,HEUKAMP L C,et al.CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer[J].Prostate,2008,68(1):42-49.DOI:10.1002/pros.20651. [34]ELLINGER J,BASTIAN P J,HAAN K I,et al.Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators[J].Int J Cancer,2008,122(1):138-143.DOI:10.1002/ijc.23057. [35]BASTIAN P J,PALAPATTU G S,YEGNASUBRAMANIAN S,et al.CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer[J].J Urol,2008,179(2):529-535.DOI:10.1016/j.juro.2007.09.038. [36]ALTIMARI A,GRIGIONI A D,BENEDETTINI E,et al.Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer[J].Am J Clin Pathol,2008,129(5):756-762.DOI:10.1309/DBPX1MFNDDJBW1FL. [37]ROUPRET M,HUPERTAN V,CATTO J W,et al.Promoter hypermethylation in circulating blood cells identifies prostate cancer progression[J].Int J Cancer,2008,122(4):952-956.DOI:10.1002/ijc.23196. [38]CHUANG C K,CHU D C,TZOU R D,et al.Hypermethylation of the CpG Islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma[J].Cancer Detect Prev,2007,31(1):59-63.DOI:10.1016/j.cdp.2006.11.001. [39]REIBENWEIN J,PILS D,HORAK P,et al.Promoter hypermethylation of GSTP1,AR,and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance[J].Prostate,2007,67(4):427-432.DOI:10.1002/pros.20533. [40]PAPADOPOULOU E,DAVILAS E,SOTIRIOU V,et al.Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer[J].Ann N Y Acad Sci,2006,1075:235-243.DOI:10.1196/annals.1368.032. [41]ALLEN D,BUTT A,CAHILL D,et al.Role of cell-free plasma DNA as a diagnostic marker for prostate cancer[J].Ann N Y Acad Sci,2004,1022:76-80.DOI:10.1196/annals.1318.013. [42]JERONIMO C,USADEL H,HENRIQUE R,et al.Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer[J].Urology,2002,60(6):1131-1135.DOI:10.1016/s0090-4295(02)01949-0. [43]GOESSL C,MüLLER M,HEICAPPELL R,et al.DNA-based detection of prostate cancer in blood,urine,and ejaculates[J].Ann N Y Acad Sci,2001,945:51-58.DOI:10.1111/j.1749-6632.2001.tb03863.x. [44]GU C Y,HUANG Y Q,HAN C T,et al.Clinical significance of urine prostatic exosomal protein in the diagnosis of prostate cancer[J].Am J Cancer Res,2019,9(5):1074-1078. [45]张雪,胡婧怡,张骏.GSTP1基因甲基化检测在前列腺癌临床诊断中的Meta分析[J].基因组学与应用生物学,2017,36(6):2157-2169.DOI:10.13417/j.gab.036.002157. ZHANG X,HU J Y,ZHANG J.Meta-analysis of GSTP1 methylation test in clinical diagnosis of prostate cancer[J].Genom Appl Biol,2017,36(6):2157-2169.DOI:10.13417/j.gab.036.002157. [46]BARRY K H,MOORE L E,LIAO L M,et al.Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer[J].Prostate,2015,75(15):1718-1725.DOI:10.1002/pros.23053. [47]KOBAYASHI P E,FONSECA-ALVES C E,RIVERA-CALDERóN L G,et al.Deregulation of E-cadherin,β-catenin,APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes[J].Res Vet Sci,2018,118:254-261.DOI:10.1016/j.rvsc.2018.03.004. [48]DANIUNAITE K,JARMALAITE S,KALINAUSKAITE N,et al. Prognostic value of RASSF1 promoter methylation in prostate cancer[J].J Urol,2014,192(6):1849-1855.DOI:10.1016/j.juro.2014.06.075. [49]DIVYYA S,NAUSHAD S M,MURTHY P V,et al.GCPⅡ modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1,BNIP3,GSTP1 and Ec-SOD[J].Mol Biol Rep,2013,40(10):5541-5550.DOI:10.1007/s11033-013-2655-7. [17]潘云虎,陈光,王智华,等.D-二聚体和C反应蛋白评估新型冠状病毒肺炎预后的临床应用价值[J].医学研究生学报,2020,33(7):748-751.DOI:10.16571/j.cnki.1008-8199.2020.07.014. PAN Y H,CHEN G,WANG Z H,et al.Clinical value of D-dimer and CRP in evaluating the prognosis of 2019 novel coronavirus-infected pneumonia[J].Journal of Medical Postgraduates,2020,33(7):748-751.DOI:10.16571/j.cnki.1008-8199.2020.07.014. [18]莫娟,刘激扬,伍松柏,等.2019冠状病毒病患者临床特征对重症化的预测作用[J].中南大学学报:医学版,2020,45(5):536-541. MO J,LIU J Y,WU S B,et al.Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease[J].J Central South Univ:Med Sci,2020,45(5):536-541. [19]余小梅,何文博,周佳莉,等.新型冠状病毒肺炎患者外周血淋巴细胞及亚群计数的变化和预后相关性分析[J].武汉大学学报(医学版),2020,23:1-5.https://doi.org/10.14188/j.1671-8852.2020.00198. [20]PóVOA P,ALMEIDA E,MOREIRA P,et al.C-reactive protein as an indicator of Sepsis[J].Intensive Care Med,1998,24(10):1052-1056.DOI:10.1007/s001340050715. [21]ESMON C T,TAYLOR F B,SNOW T R.Inflammation and coagulation:linked processes potentially regulated through a common pathway mediated by protein C[J].Thromb Haemost,1991,66(1):160-165. [22]付俊,罗宇鸿.白介素6、超敏C反应蛋白、血清降钙素原在早期感染诊断中的意义分析[J].临床医药文献电子杂志,2018,5(A2):194,199.DOI:10.16281/j.cnki.jocml.2018.a2.138. [23]于歆,马新华,艾宇航.血清降钙素原在免疫受损危重患者感染诊断中的临床意义[J].中华危重病急救医学,2015,27(6):477-483.DOI:10.3760/cma.j.issn.2095-4352.2015.06.012. YU X,MA X H,AI Y H,et al.Diagnostic value of serum procalcitonin for infection in the immunocompromised critically ill patients with ;suspected infection[J].Chinese Critical Care Medicine,2015,27(6):477-483.DOI:10.3760/cma.j.issn.2095-4352.2015.06.012. [24]徐钰,郭杨,曹宝平,等.联合降钙素原和D-二聚体检测对急诊感染患者病情判断的临床意义[J].中国急救医学,2015,35(4):331-334.DOI:10.3969/j.issn.1002-1949.2015.04.010. [25]HUNAG C L,WANG Y M,LI X W,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China [J].Lancet,2020,395 (10223):497-506.DOI:10.1016/S0140-6736(20)30183-5. [26]TANG N,LI D J,WANG X,et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J].J Thromb Haemost,2020,18(4):844-847.DOI:10.1111/jth.14768. [27]ZHOU F,YU T,DU R H,et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:a retrospective cohort study[J].Lancet,2020,395(10229):1054-1062.DOI:10.1016/S0140-6736(20)30566-3. [28]GUAN W J,NI Z Y,HU Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020,382(18):1708-1720.DOI:10.1056/nejmoa2002032. |
[1] | WANG Zhe, DONG Zhihao, ZHENG Hao, KONG Wencheng, ZHANG Yukuan, ZHANG Qiuyue, HAN Jing. Construction of Optimized Treatment Plan of Acupuncture for Migraine Based on Entropy Weight-TOPSIS Method [J]. Chinese General Practice, 2023, 26(34): 4336-4342. |
[2] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[3] | JIAN Qiufeng, XU Ronghua, YAO Qian, ZHOU Yuanyuan. A Meta-analysis of the Prevalence and Influencing Factors of Post-stroke Cognitive Impairment in Chinese Elderly Patients [J]. Chinese General Practice, 2023, 26(32): 4070-4079. |
[4] | JIA Yu, ZHOU Zitong, CAO Xuehua, HU Wanqin, XIANG Feng, XIONG Langyu, WANG Xiaoxia. Incidence of Perimenopausal Syndrome in Chinese Women Aged 40 to 65 Years: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4080-4088. |
[5] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[6] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[7] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[8] | ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832. |
[9] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[10] | HE Li, ZHANG Yifan, SHEN Xuechun, SUN Yan, ZHAO Yang. Prevalence Trends of Multimorbidity among Residents in Mainland China: a Meta-analysis [J]. Chinese General Practice, 2023, 26(29): 3599-3607. |
[11] | CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470. |
[12] | LIN Yang, WANG Fang, WANG Han, WU Rong, WANG Yao, XU Ziyao, WANG Xu, WANG Yanding. Prevalence of Frailty in Elderly Patients with Comorbidity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(25): 3185-3193. |
[13] | YIN Zhaoxia, KONG Chongyu, ZOU Xianhui, LI Chuang, HUANG Yin, FENG Yang, WANG Yunfei, GONG Weijie. Traditional Chinese Medicine Disease Spectrum Analysis in Outpatient Clinics of Contracted Residents by Family Doctors in Shenzhen Community Health Service Centers [J]. Chinese General Practice, 2023, 26(25): 3112-3117. |
[14] | ZHANG Yunxu, WANG Tingting, WEI Junling, XING Yanyun, SU Li. A Newly Discovered Disease Affecting Women's Physical and Mental Health: Research Status and Expert Consensus Interpretation of Persistent Genital Arousal Disorder [J]. Chinese General Practice, 2023, 26(23): 2830-2835. |
[15] | ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||